FDA registered, VeinStay^TM has been shown to increase the success rate of 1st venipuncture by over 20%.

VeinStay^TM is proven to be helpful in difficult situations. During use, the tines of the VeinStay^TM are pressed against the skin of the patient such that they sit astride the vein to be accessed.

The distance between the tines varies to accommodate vein widths. The vein is accentuated and thus easier to see and also control those "rolling veins".

Primary Health Network (PHN), a prominent health care facility, has agreed to conduct a clinical trial for CRG in November and December of this year.

PHN and CRG have established oversight protocols and independent observation for the trial.

Based upon the results of the trial, CRG will explore future marketing potentials.